Baxter/BAX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Baxter

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

Ticker

BAX

Sector

Healthcare

Trading on

NYSE

Industry

Health Care Equipment and Supplies

Headquarters

Deerfield, United States

Employees

60,000
Website
www.baxter.com

Baxter Metrics

BasicAdvanced
$17B
Market cap
6.30
P/E ratio
$5.22
EPS
0.61
Beta
$1.16
Dividend rate
3.53%
Dividend yield
$17B
0.61
$1.16
1.477
0.88
140.085
172.07
22.16%
3.25%
3.56%
-0.42%
6.3
1.12
2.05
-4.02
23.55
3.53%
2.98%
-207.04%
8.01%
36.10%
5.78%

What the Analysts think about Baxter

Analyst Ratings

Majority rating from 17 analysts.
Hold

Baxter Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.03% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.6B
-7.54%
Net income
$37M
-84.90%
Profit margin
1.03%
-83.65%

Baxter Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.04%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.55
$0.68
$0.88
$0.65
-
Expected
$0.61
$0.67
$0.86
$0.61
$0.66
Surprise
-9.54%
1.84%
1.82%
7.04%
-

Baxter News

AllArticlesVideos

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Business Wire·2 months ago

Baxter Reports First-Quarter 2024 Results

Business Wire·2 months ago

Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Baxter stock?

Baxter (BAX) has a market cap of $17B as of July 03, 2024.

What is the P/E ratio for Baxter stock?

The price to earnings (P/E) ratio for Baxter (BAX) stock is 6.3 as of July 03, 2024.

Does Baxter stock pay dividends?

Yes, the Baxter (BAX) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $1.16 and the yield is 3.53%. Baxter has a payout ratio of 22.16% on a trailing twelve-month basis.

When is the next Baxter dividend payment date?

The next Baxter (BAX) dividend payment date is unconfirmed.

What is the beta indicator for Baxter?

Baxter (BAX) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Baxter stock

Buy or sell Baxter stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing